Multiple Sclerosis Emerging Therapies: What 2026 Holds for Women’s Health and Personalized Care
Did you know? A single‑center review of 58 pregnancies in women with multiple sclerosis (MS) found that staying on natalizumab during pregnancy eliminated relapses, while 45% of those who stopped the drug experienced disease progression.
Imagine a future where every woman with MS can plan a family without fearing a flare‑up, and where a handful of novel drugs—like BTK inhibitors and CAR T‑cell therapy—offer real alternatives for patients who have exhausted existing options. 2026 is already shaping that reality, and clinicians who grasp these shifts will be the ones delivering truly individualized care.
Why the Therapeutic Landscape Is Shifting
MS management has moved from a one‑size‑fits‑all approach to a nuanced strategy that accounts for disease course, patient characteristics, and life stage. As NeuroVoices highlighted, the heterogeneity of MS means that what works in early disease may not suffice later, prompting a search for therapies with fresh mechanisms of action.
BTK Inhibitors: A Promise on Hold
Bruton tyrosine kinase (BTK) inhibitors target B‑cell signaling pathways distinct from those of current disease‑modifying therapies (DMTs). Although several candidates have faced delays or cancellation, ongoing trials continue to show promise, and experts like Katrina Bawden, MSN, MSCN, FNP‑Ca, remain hopeful that at least one BTK inhibitor will reach the market this year.
Pro Tip: Keep an eye on trial registries and conference abstracts for updates on BTK inhibitor efficacy and safety profiles, especially in patients with progressive forms of MS.
CAR T‑Cell Therapy: From Cancer to Autoimmunity
CAR T‑cell therapy, a breakthrough in oncology, is now being explored for MS. Early‑stage data suggest that engineered T cells can selectively target pathogenic immune cells, potentially resetting the immune system. While only a few MS patients have received CAR T to date, the initial outcomes are encouraging.
For clinicians, the key question is timing: When is a patient ready for a cellular therapy that could radically alter disease trajectory? Ongoing studies aim to define eligibility criteria that balance risk and reward.
Pregnancy Management: The Natalizumab Paradigm Shift
Historically, women with MS were told to avoid pregnancy or discontinue therapy—a stance that often led to severe relapses. Since 2019, the conversation has changed, driven by emerging evidence and updated guidelines.
At the 2025 CMSC Annual Meeting, Bawden presented a retrospective analysis of 58 pregnancies (2008‑2024) at Rocky Mountain MS Clinic:
- 20 women chose to stay on natalizumab (Tysabri) throughout pregnancy, receiving doses every 8 weeks with the last dose at 32‑34 weeks.
- None of these women experienced a relapse during pregnancy or the postpartum period.
- Among the 38 women who stopped natalizumab, 17 (45%) showed clinical or radiographic progression.
These findings have sparked a collaborative effort to conduct a national meta‑analysis of natalizumab use in pregnancy, aiming to provide clinicians with robust data for shared decision‑making.
Expert Insight: “We’re giving women the power to choose whether to stay on natalizumab, backed by real‑world outcomes that show clear benefits,” Bawden noted.
Unmet Needs: Menopause and GLP‑1 Medications
Beyond pregnancy, two areas remain under‑explored:
Menopause and MS Activity
For years, the prevailing belief was that menopause neither worsened nor improved MS. Bawden argues that this assumption may mask critical disease dynamics, urging researchers to investigate whether hormonal changes influence immune activity and whether tailored therapies are needed for post‑menopausal patients.
GLP‑1 Agonists: An Unexpected Ally?
GLP‑1 medications, originally developed for diabetes, are gaining attention for their weight‑loss and anti‑inflammatory properties. Anecdotally, many MS patients on GLP‑1s report feeling “much better,” prompting questions about potential direct effects on neuroinflammation.
Pro Tip: When considering GLP‑1 therapy for MS patients, monitor both metabolic parameters and neurologic outcomes to capture any dual benefits.
What Lifestyle Factors Are Reinforcing Medical Advances?
While drug development takes center stage, lifestyle interventions continue to complement therapeutic gains. A recent ACTRIMS Forum presentation highlighted that adherence to a Mediterranean‑style diet correlated with longer leukocyte telomere length—a marker of biological aging—potentially slowing disability progression in early MS (source).
Integrating diet counseling with emerging DMTs could amplify patient outcomes, especially for women navigating pregnancy, menopause, or weight‑related comorbidities.
Actionable Strategies for Clinicians in 2026
- Stay Informed: Regularly review abstracts from the ACTRIMS Forum and other MS conferences for updates on BTK inhibitors and CAR T trials.
- Personalize Pregnancy Plans: Use natalizumab outcome data to discuss continuation versus cessation with patients, emphasizing the 0% relapse rate observed in those who stayed on therapy.
- Screen for Menopausal Transitions: Incorporate hormone‑related symptom assessments into routine visits for women over 45.
- Consider GLP‑1 Options: Evaluate metabolic health and discuss potential off‑label benefits with patients interested in weight management.
- Promote Neuroprotective Diets: Offer Mediterranean diet resources as adjunctive support for disease‑modifying strategies.
By weaving these evidence‑based practices into everyday care, clinicians can turn the promise of emerging therapies into tangible improvements for patients.
Frequently Asked Questions
What are BTK inhibitors and why are they important for MS?
BTK inhibitors block a key enzyme in B‑cell signaling, offering a novel mechanism distinct from current DMTs. Early trials suggest they may be effective for patients who do not respond to existing therapies.
Is CAR T‑cell therapy ready for routine MS use?
Currently, CAR T is in early investigational stages for MS. Safety and efficacy data are still being gathered, and widespread adoption will depend on forthcoming trial results.
Can women safely stay on natalizumab throughout pregnancy?
Data from a single US center (58 pregnancies, 20 continued natalizumab) showed no relapses during pregnancy or postpartum, whereas stopping the drug was associated with a 45% progression rate.
Do GLP‑1 medications directly affect MS disease activity?
Evidence is anecdotal; though, patients report improved well‑being, prompting research into possible anti‑inflammatory effects beyond weight loss.
How does menopause influence MS?
The relationship remains unclear. More research is needed to determine whether hormonal changes alter disease activity or require tailored treatment approaches.
What emerging therapy or lifestyle change do you think will reshape MS care the most this year? Share your thoughts in the comments below, and explore more insights on personalized MS treatment in our guide to individualized MS care.
